Absorption And Dispersion Of Injected Drugs
injection) is indicated as an adjuvant to increase the absorption and
dispersion of other injected drugs.
Hydase™ is indicated as an
adjuvant in subcutaneous fluid administration for achieving hydration.
Hydase™ is indicated as an
adjuvant in subcutaneous urograpy for improving resorption of radiopaque.
DOSAGE AND ADMINISTRATION
Do not administer Hydase
intravenously because hyaluronidase enzyme is rapidly inactivated with
Hydase™ may be administered for
infiltration use, interstitial use, intramuscular use, intraocular use,
retrobulbar use, soft tissue use and subcutaneous use.
Visually inspect parenteral
drug products for particulate matter and discoloration prior to administration,
whenever the solution and container permit.
Always use aseptic precautions.
Dosage For Absorption And Dispersion
Of Subcutaneously Injected Drugs
Absorption and dispersion of
other injected drugs may be enhanced by adding 50 to 300 Units, most typically
150 Units of hyaluronidase, to the injection solution.
It is recommended that
appropriate references be consulted regarding physical or chemical
incompatibilities before adding Hydase™ to a solution containing another drug.
Dosage For Hypodermoclysis
Insert needle with aseptic
precautions. With tip lying free and movable between skin and muscle, begin
clysis; fluid should start in readily without pain or lump. Then inject Hydase™
(hyaluronidase injection) into rubber tubing close to needle.
An alternate method is to
inject Hydase™ under skin prior to clysis. 150 Units will facilitate absorption
of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe
effect closely, with same precautions for restoring fluid and electrolyte
balance as in intravenous injections. The dose, the rate of injection, and the type
of solution (saline, glucose, Ringer's, etc.) must be adjusted carefully to the
individual patient. When solutions devoid of inorganic electrolytes are given
by hypodermoclysis, hypovolemia may occur. This may be prevented by using
solutions containing adequate amounts of inorganic electrolytes and/or
controlling the volume and speed of administration.
Hydase™ may be added to small
volumes of solution (up to 200 mL), such as small clysis for infants or
solutions of drugs for subcutaneous injection. For infants and children less
than 3 years old, the volume of a single clysis should be limited to 200 mL;
and in premature infants or during the neonatal period, the daily dosage should
not exceed 25 mL/kg of body weight; the rate of administration should not be
greater than 2 mL per minute. For older patients, the rate and volume of
administration should not exceed those employed for intravenous infusion.
Dosage For Subcutaneous Urography
The subcutaneous route of administration of urographic
contrast media is indicated when intravenous administration cannot be
successfully accomplished, particularly in infants and small children. With the
patient prone, 75 Units of Hydase™ (hyaluronidase injection) is injected
subcutaneously over each scapula, followed by injection of the contrast medium
at the same sites.
Dosage Forms And Strengths
Injection 150 USP Units/mL single dose vials.
Storage And Handling
Hydase™ (hyaluronidase injection) Bovine is supplied
sterile as 150 units/mL bovine of hyaluronidase in a single-dose glass vial
containing 1 mL.
NDC 17478-560-01 Package of 1 vial.
NDC 17478-560-06 Package of 6 vials.
NDC 17478-560-10 Package of 10 vials.
Not recommended for IV Use.
Store in a refrigerator at 2° to 8°C (36° to 46°F).
DO NOT FREEZE.
Manufactured by: Akorn, Inc. Lake Forest, IL 60045.
Revised: Oct 2015